Atlas Trials

Single Dose Study to Evaluate Dose-proportionality of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets

Clinical trial NCT05416762 · COMPLETED

Trial details

NCT number
NCT05416762
Sponsor
Seasons Biotechnology (Taizhou) Co., Ltd.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Major Depressive Disorder (MDD
Start date
2022-09-19
Primary completion
2022-11-25
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.